Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

Official Title

A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE)

Details

The duration per participant will be up to 152 weeks.

Keywords

Eosinophilic Oesophagitis, Esophagitis, Eosinophilic Esophagitis, Dupilumab

Eligibility

Locations

  • UCSF - Parnassus Heights- Site Number : 8400020
    San Francisco California 94143 United States
  • United Gastroenterologists - Murrieta- Site Number : 8400001
    Murrieta California 92563 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Sanofi
ID
NCT06101095
Phase
Phase 4 Eosinophilic Esophagitis Research Study
Study Type
Interventional
Participants
Expecting 64 study participants
Last Updated